Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors
Molecules · 21.08.2024 · 29 (16) · 3944
DOI: 10.3390/molecules29163944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 21.08.2024. Verfasst von Jessica L Ortega-Balleza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactamases, Zinc. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigacipn y Posgrado del Instituto Politecnico Nacional, Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional.
Abstract (Originalsprache)
Currently, antimicrobial resistance (AMR) is a serious health problem in the world, mainly because of the rapid spread of multidrug-resistant (MDR) bacteria. These include bacteria that produce β-lactamases, which confer resistance to β-lactams, the antibiotics with the most prescriptions in the world. Carbapenems are particularly noteworthy because they are considered the ultimate therapeutic option for MDR bacteria. However, this group of antibiotics can also be hydrolyzed by β-lactamases, including metallo-β-lactamases (MBLs), which have one or two zinc ions (Zn2+) on the active site and are resistant to common inhibitors of serine β-lactamases, such as clavulanic acid, sulbactam, tazobactam, and avibactam. Therefore, the design of inhibitors against MBLs has been directed toward various compounds, with groups such as nitrogen, thiols, and metal-binding carboxylates, or compounds such as bicyclic boronates that mimic hydrolysis intermediates. Other compounds, such as dipicolinic acid and aspergillomarasmin A, have also been shown to inhibit MBLs by chelating Zn2+. In fact, recent inhibitors are based on Zn2+ chelation, which is an important factor in the mechanism of action of most MBL inhibitors. Therefore, in this review, we analyzed the current strategies for the design and mechanism of action of metal-ion-binding inhibitors that combat MDR bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Ciudad de México 03940, Mexico.
- Departamento de Ciencias Médicas y de la Vida, Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán 47810, Mexico.
ORCID-Profile: Jessica L Ortega-Balleza, Lenci K Vázquez-Jiménez, Eyra Ortiz-Pérez, Guadalupe Avalos-Navarro, Gildardo Rivera
Förderung
- Secretaria de Investigacipn y Posgrado del Instituto Politecnico Nacional
- Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional
Zitieren
APA
Ortega-Balleza, J. L., Vázquez-Jiménez, L. K., Ortiz-Pérez, E., Avalos-Navarro, G., Paz-González, A. D., Lara-Ramírez, E. E., & Rivera, G. (2024). Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors. Molecules, 29(16), 3944. https://doi.org/10.3390/molecules29163944
Vancouver
Ortega-Balleza JL, Vázquez-Jiménez LK, Ortiz-Pérez E, Avalos-Navarro G, Paz-González AD, Lara-Ramírez EE, et al. Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors. Molecules. 2024;29(16):3944. doi:10.3390/molecules29163944
BibTeX
@article{OrtegaBalleza2024,
author = {Ortega-Balleza, Jessica L and Vázquez-Jiménez, Lenci K and Ortiz-Pérez, Eyra and Avalos-Navarro, Guadalupe and Paz-González, Alma D and Lara-Ramírez, Edgar E and Rivera, Gildardo},
title = {Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors},
journal = {Molecules},
year = {2024},
volume = {29},
number = {16},
pages = {3944},
doi = {10.3390/molecules29163944}
}
EUVIMED